<DOC>
	<DOCNO>NCT02806973</DOCNO>
	<brief_summary>This study investigate body process LY900018 effect LY900018 body . The study drug deliver participant 's nostril ( ) ( intranasally ) twice four study period . The study expect last 50 day participant . The study open adult type 1 type 2 diabetes last 50 day .</brief_summary>
	<brief_title>A Study Single Repeated Doses Glucagon Participants With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Male female history Type 1 Type 2 insulinusing diabetes least 1 year duration ( basal , basal bolus , mealtime , twice day premixed insulin ) A female participant must meet one follow criterion : Participant childbearing potential agrees use one accept contraceptive regimen least 28 day prior first administration study drug , study least 30 day last dose study drug Participant nonchildbearing potential , define surgically sterile ( i.e . undergone complete hysterectomy , bilateral oophorectomy , tubal ligation ) menopausal state ( least 1 year without menses ) Participant body mass index ( BMI ) great equal 18.50 kilogram per square meter ( kg/m² ) 35.00 kg/m² Light , non exsmokers In good general health condition could influence outcome trial , judgment Investigator good candidate study base review available medical history , physical examination clinical laboratory evaluation Females pregnant , actively attempt get pregnant , lactate History significant hypersensitivity glucagon relate product well severe hypersensitivity reaction ( angioedema ) drug Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease Known presence rare hereditary problem galactose /or lactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Presence clinically significant finding nasal examination bilateral anterior rhinoscopy , structural abnormality , nasal polyp , mark septal deviation , nasal tumor Nasal surgery previous 28 day Day 1 study Daily use systemic betablocker drug , indomethacin , warfarin anticholinergic drug previous 28 day Day 1 study Any concomitant maintenance therapy would influence outcome trial compromise safety participant , discretion Investigator Sponsor , previous 28 day Day 1 study Significant history drug dependency alcohol abuse Any clinically significant illness previous 28 day Day 1 study Any history tuberculosis and/or prophylaxis tuberculosis Positive urine screen alcohol and/or drug abuse Positive result human immunodeficiency virus ( HIV ) Antigen/Antibody ( Ag/Ab ) Combo , Hepatitis B surface Antigen ( HBsAG ( B ) ( hepatitis B ) ) antiHepatitis C Virus ( HCV ( C ) ) test Concurrent participation intention participate another clinical trial study Participants take Investigational Product ( another clinical trial ) previous 28 day Day 1 study already participate clinical study Participants donate 50 milliliter ( mL ) blood previous 28 day Day 1 study Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day Day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>